Industry: Pharmaceuticals (See others in industry)
Address:Date | FilingType | Incremental Cash | Link to Raw Filing | |||
---|---|---|---|---|---|---|
2025-05-12 | Amended | $6,499,590 | $1,294,000 | Debt Only | 06b | SEC link |
2024-10-03 | New | $5,205,590 | $5,205,590 | Debt Only | 06b | SEC link |
Name | Role |
---|---|
John Beaver | Director, Executive |
Jack Hoppin | Director |
Karl Schmidt | Executive |
Kenan Turnacioglu | Director, Executive |